{"count": 1, "results": [{"_id": "36902821", "pmid": 36902821, "pmcid": "PMC10004435", "title": "Reduction in the Risk of Peripheral Neuropathy and Lower Decrease in Kidney Function with Metformin, Linagliptin or Their Fixed-Dose Combination Compared to Placebo in Prediabetes: A Randomized Controlled Trial", "journal": "J Clin Med", "authors": ["Gabriel R", "Boukichou-Abdelkader N", "Gilis-Januszewska A", "Makrilakis K", "Gómez-Huelgas R", "Kamenov Z", "Paulweber B", "Satman I", "Djordjevic P", "Alkandari A", "Mitrakou A", "Lalic N", "Egido J", "Más-Fontao S", "Calvet JH", "Pastor JC", "Lindström J", "Lind M", "Acosta T", "Silva L", "Tuomilehto J", "On Behalf Of The E-Predice Consortium"], "date": "2023-03-03T00:00:00Z", "doi": "10.3390/jcm12052035", "meta_date_publication": "2023 Mar 3", "meta_volume": "12", "meta_issue": "5", "meta_pages": "", "score": 50273.92, "text_hl": "Results: Compared to the placebo, the proportion of @<m>DISEASE_Small_Fiber_Neuropathy</m> @DISEASE_MESH:D000071075 @@@SFPN@@@ was reduced by 25.1% (95% CI:16.3-33.9) with @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ alone, by 17.3% (95% CI 7.4-27.2) with @CHEMICAL_Linagliptin @CHEMICAL_MESH:D000069476 @@@linagliptin@@@ alone, and by 19.5% (95% CI 10.1-29.0) with the combination @CHEMICAL_Linagliptin @CHEMICAL_MESH:D000069476 @@@linagliptin@@@/@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ (p < 0.0001 for all comparisons). eGFR remained +3.3 mL/min (95% CI: 0.38-6.22) higher with the combination @CHEMICAL_Linagliptin @CHEMICAL_MESH:D000069476 @@@linagliptin@@@/@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ than with the placebo (p = 0.03). ", "citations": {"NLM": "Gabriel R, Boukichou-Abdelkader N, Gilis-Januszewska A, Makrilakis K, Gómez-Huelgas R, Kamenov Z, Paulweber B, Satman I, Djordjevic P, Alkandari A, Mitrakou A, Lalic N, Egido J, Más-Fontao S, Calvet JH, Pastor JC, Lindström J, Lind M, Acosta T, Silva L, Tuomilehto J, On Behalf Of The E-Predice Consortium. Reduction in the Risk of Peripheral Neuropathy and Lower Decrease in Kidney Function with Metformin, Linagliptin or Their Fixed-Dose Combination Compared to Placebo in Prediabetes: A Randomized Controlled Trial J Clin Med. 2023 Mar 3;12(5):. PMID: 36902821", "BibTeX": "@article{36902821, title={Reduction in the Risk of Peripheral Neuropathy and Lower Decrease in Kidney Function with Metformin, Linagliptin or Their Fixed-Dose Combination Compared to Placebo in Prediabetes: A Randomized Controlled Trial}, author={Gabriel R and Boukichou-Abdelkader N and Gilis-Januszewska A and Makrilakis K and Gómez-Huelgas R and Kamenov Z and Paulweber B and Satman I and Djordjevic P and Alkandari A and Mitrakou A and Lalic N and Egido J and Más-Fontao S and Calvet JH and Pastor JC and Lindström J and Lind M and Acosta T and Silva L and Tuomilehto J and On Behalf Of The E-Predice Consortium}, journal={J Clin Med}, volume={12}, number={5}}"}}]}